Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemetrexed + cisplatin
- Development stage
- Phase 4
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Pemetrexed + cisplatin is a combination chemotherapy regimen consisting of two small molecule antineoplastic agents. Pemetrexed, marketed as Alimta, is an antifolate that inhibits several enzymes involved in folate metabolism and DNA synthesis, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Cisplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. This combination is FDA-approved for the first-line treatment of malignant pleural mesothelioma (in patients not eligible for curative surgery) and non-squamous non-small cell lung cancer (NSCLC). The regimen works by disrupting DNA replication and cell division in cancer cells. It is administered intravenously in cycles every 21 days[1][2][3][4][6].
- Brand names
- Alimta + Platinol
- Other names
- pemetrexed and cisplatinAlimta and cisplatin
02
Targets
DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on pemetrexed + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemetrexed + cisplatin.